Table 2 Common ( ≥ 10%) adverse events (n = 34)

From: Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study

Variables, n (%)

All grades

Grade 3

Grade 4

Stomatitis

21 (61.7)

1 (2.9)

0 (0.0)

Oedema

17 (50.0)

0 (0.0)

0 (0.0)

Nausea

14 (41.2)

1 (2.9)

0 (0.0)

Papulopustular rash

14 (41.2)

0 (0.0)

0 (0.0)

Palmar–plantar erythrodysesthesia syndrome

14 (41.2)

0 (0.0)

0 (0.0)

Fatigue

14 (41.2)

2 (5.9)

0 (0.0)

Fever

10 (29.4)

1 (2.9)

0 (0.0)

Pruritus

9 (26.5)

0 (0.0)

0 (0.0)

Anorexia

9 (26.5)

0 (0.0)

0 (0.0)

Abdominal pain

8 (23.5)

3 (8.8)

0 (0.0)

Diarrhoea

8 (23.5)

0 (0.0)

0 (0.0)

Vomiting

7 (20.6)

0 (0.0)

0 (0.0)

Dyspnoea

7 (20.6)

1 (2.9)

0 (0.0)

Anaemia

5 (14.7)

4 (11.8)

0 (0.0)

Cholangitis

5 (14.7)

4 (11.8)

0 (0.0)

Upper respiratory infection

5 (14.7)

0 (0.0)

0 (0.0)

Blood bilirubin increased

5 (14.7)

2 (5.9)

0 (0.0)

Back pain

5 (14.7)

0 (0.0)

0 ((0.0)

Neutrophil count decreased

4 (11.8)

1 (2.9)

0 (0.0)

Productive sputum

4 (11.8)

0 (0.0)

0 (0.0)